ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$23.76 USD
-0.03 (-0.13%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $23.76 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum A VGM
ArriVent BioPharma, Inc. (AVBP) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$38.40 | $41.00 | $36.00 | 61.41% |
Price Target
Based on short-term price targets offered by five analysts, the average price target for ArriVent BioPharma, Inc. comes to $38.40. The forecasts range from a low of $36.00 to a high of $41.00. The average price target represents an increase of 61.41% from the last closing price of $23.79.
Analyst Price Targets (5 )
Broker Rating
ArriVent BioPharma, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Of the six recommendations deriving the current ABR, six are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 5 | 5 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/11/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
9/10/2024 | Goldman Sachs | Christopher Johnson | Strong Buy | Strong Buy |
8/16/2024 | H.C. Wainwright & Co. | Robert Burns | Strong Buy | Strong Buy |
8/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/15/2024 | LifeSci Capital | Sam Slutsky | Strong Buy | Strong Buy |
7/22/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 6 |
Average Target Price | $38.40 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -0.82 |
AVBP FAQs
ArriVent BioPharma, Inc. (AVBP) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for ArriVent BioPharma, Inc. (AVBP) is $38.40. The current on short-term price targets is based on 4 reports.
The forecasts for ArriVent BioPharma, Inc. (AVBP) range from a low of $36 to a high of $41. The average price target represents a increase of $61.62 from the last closing price of $23.76.
The current UPSIDE for ArriVent BioPharma, Inc. (AVBP) is 61.62%
Based on short-term price targets offered by five analysts, the average price target for ArriVent BioPharma, Inc. comes to $38.40. The forecasts range from a low of $36.00 to a high of $41.00. The average price target represents an increase of 61.41% from the last closing price of $23.79.